Recognizing the need for better information about the safety of consumer products, Congress directed the Food and Drug Administration (FDA) to establish an active surveillance system for monitoring post-market drugs and medical products. In May 2008, FDA unveiled the Sentinel Initiative – a national electronic data system designed to track drug and medical product performance and ultimately to improve public health.
On January 11, the Engelberg Center convened the 2nd Annual Sentinel Initiative Public Workshop, bringing together key stakeholders to explore a range of issues, including recently completed FDA contracts committed to the development of the Sentinel System and ongoing pilot projects tracking medical product safety. Broader discussion topics focused on maintaining patient privacy while conducting medical product safety surveillance; developing the Sentinel System as a national resource for medical product safety surveillance that would allow access to others beyond FDA, and developing a multi-purpose distributed system to conduct not only safety surveillance work but also for comparative effectiveness research, product quality assessment, and other types of health questions.
Convened by the Engelberg Center for Health Care Reform at Brookings and supported by a grant from the Food and Drug Administration.
Agenda
-
January 11
-
Welcome and Overview
-
Keynote Address
Margaret Hamburg Commissioner - U.S. Food and Drug Administration -
Session I – Reports from Selected Sentinel Contractors: Legal Issues, Database Models, and Evaluation of Existing Methods
-
Session II – Update on FDA’s Current Medical Product Safety Initiatives
Richard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care Institute -
Session III – Issues of Broad Interest in Implementing Active Surveillance: Panel Discussions on Patient Privacy, Sentinel as a National Resource, and Building a Multi-Purpose Health IT Network
-
Closing Remarks
-